[1] O. Schnell, W. Otter, and E. Standl, “The Munich Myocardial Infarction Registry: translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice,” Diabetes care, vol. 32, supplement 2, pp. S326–S330, 2009.
[2] S. Van Dieren, J. W. J. Beulens, Y. T. Van Der Schouw, D. E. Grobbee, and B. Neal, “The global burden of diabetes and its complications: an emerging pandemic,” European 
[3] C. Voulgari, D. Papadogiannis, and N. Tentolouris, “Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies,” Vascular Health and Risk Management, vol. 6, pp. 883–903, 2010.
[4] S. Boudina and E. D. Abel, “Diabetic cardiomyopathy revisited,” Circulation, vol. 115, no. 25, pp. 3213–3223, 2007.
[5] Theosophy, “Ancient landmarks: plato and aristotle,” Theosophy, vol. 27, no. 11, pp. 483–491, 1939.
[6] S. Zoungas and A. Patel, “Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies,” Annals of the New York Academy of Sciences, vol. 1212, no. 1, pp. 29–40, 2010.
[7] T. D. Miller, R. F. Redberg, and F. J. T. Wackers, “Screening asymptomatic diabetic patients for coronary artery disease: why not?” Journal of the American College of Cardiology, vol. 48, no. 4, pp. 761–764, 2006.
[8] G. A. Beller, “Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective?” Journal of the American College of Cardiology, vol. 49, no. 19, pp. 1918– 1923, 2007.
[9] P. Poirier, J.-P. Després, and O. F. Bertrand, “Identifying which patients with diabetes should be tested for the presence of coronary artery disease—the importance of baseline electrocardiogram and exercise testing,” Canadian Journal of Cardiology, vol. 22, supplement A, pp. 9A–15A, 2006.
[10] A. Aneja, W. H. W. Tang, S. Bansilal, M. J. Garcia, and M. E. Farkouh, “Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options,” American Journal of Medicine, vol. 121, no. 9, pp. 748–757, 2008.
[11] D. Raev, “Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocar- diographic study of young type I diabetic patients,” Diabetes Care, vol. 17, no. 7, pp. 633–639, 1994.
[12] C. M. Schannwell, M. Schneppenheim, S. Perings, G. Plehn, and B. E. Strauer, “Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy,” Cardiology, vol. 98, no. 1-2, pp. 33–39, 2002.
[13] T. H. Kim, S. H. Yu, S. H. Choi et al., “Pericardial fat amount is an independent risk factor of coronary artery stenosis assessed by multidetector-row computed tomography: the Korean Atherosclerosis Study 2,” Obesity (Silver Spring), vol. 19, no. 5, pp. 1028–1034, 2011.
[14] M. J. Babcock, E. Z. Soliman, J. Ding, R. A. Kronmal, and D. C. Goff Jr., “Pericardial fat and atrial conduction abnormalities in the Multiethnic Study of atherosclerosis (MESA),” Obesity (Silver Spring), vol. 19, no. 1, pp. 179–184, 2011.
[15] M. A. G omez-Marcos,  ́ J. I. Recio-Rodrıguez, E. Rodrıguez- Snchez et al., “Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol,” BMC Public Health, vol. 10, Article ID 143, 2010.
[16] B. P. Wiik, A. C. K. Larstorp, A. Høieggen et al., “Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: the LIFE Study,” 
[17] V. Barrios, C. Escobar, A. Calder on,  ́ R. Echarri, S. Barrios, and J. Navarro-Cid, “Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study,” Journal of the Renin- Angiotensin-Aldosterone System, vol. 10, no. 3, pp. 168–173, 2009.
[18] P. M. Okin, R. B. Devereux, M. S. Nieminen et al., “Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study,” Journal of the American College of Cardiology, vol. 38, no. 2, pp. 514–520, 2001.
[19] T. N. James, “The variable morphological coexistence of apoptosis and necrosis in human myocardial infarction: significance for understanding its pathogenesis, clinical course, diagnosis and prognosis,” Coronary Artery Disease, vol. 9, no. 5, pp. 291–307, 1998.
[20] J. A. Beckman, P. Libby, and M. A. Creager, “Diabetes mellitus, the metabolic syndrome, and atherosclerotic vascular disease,” in Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, P. Libby, R. O. Bonow, D. L. Mann, and D. P. Zipes, Eds., pp. 1094–1105, Saunders Elsevier, Philadelphia, Pa, USA, 8th edition, 2008.
[21] M. Dweck, I. W. Campbell, D. Miller, and C. M. Francis, “Clinical aspects of silent myocardial ischaemia: with partic- ular reference to diabetes mellitus,” British Journal of Diabetes and Vascular Disease, vol. 9, no. 3, pp. 110–116, 2009.
[22] E. Cosson, J. R. Attali, and P. Valensi, “Markers for silent myocardial ischemia in diabetes. Are they helpful?” Diabetes and Metabolism, vol. 31, no. 2, pp. 205–213, 2005.
[23] A. Avignon, A. Sultan, C. Piot et al., “Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients,” Diabetes Care, vol. 30, no. 11, pp. 2934–2939, 2007.
[24] T. M. E. Davis, P. Fortun, J. Mulder, W. A. Davis, and D. G. Bruce, “Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study,” Diabetologia, vol. 47, no. 3, pp. 395–399, 2004.
[25] F. J. Wackers, L. H. Young, S. E. Inzucchi et al., “Detection of ischemia in asymptomatic diabetics (DIAD) investigators: detection of silent myocardial ischemia in asymptomatic diabetic subjects,” Diabetes Care, vol. 27, no. 8, pp. 1954– 1961, 2004.
[26] A. Kumar, R. J. Prineas, A. M. Arnold et al., “Prevalence, prognosis, and implications of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults cardiovascular health study,” Circulation, vol. 118, no. 25, pp. 2790–2796, 2008.
[27] P. K. Stein, D. Sanghavi, P. P. Domitrovich, R. A. Mackey, and P. Deedwania, “Ambulatory ECG-based T-wave alternans predicts sudden cardiac death in high-risk post-MI patients with left ventricular dysfunction in the EPHESUS study,” Journal of Cardiovascular Electrophysiology, vol. 19, no. 10, pp. 1037–1042, 2008.
[28] D. Aguilar, S. Z. Goldhaber, D. J. Gans et al., “Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy,” American Journal of Cardiology, vol. 94, no. 3, pp. 337–339, 2004.
[29] C. Pappone and V. Santlnelli, “Cardiac electrophysiology in diabetes,” Minerva Cardioangiologica, vol. 58, no. 2, pp. 269– 276, 2010.
[30] D. Lloyd-Jones, R. J. Adams, T. M. Brown et al., “American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association,” Circulation, vol. 121, no. 7, pp. e46–e215, 2010.
[31] J. Shirani and V. Dilsizian, “Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome?” Current Cardiology Reports, vol. 12, no. 2, pp. 140–146, 2010.
[32] S. Bacci, M. Villella, A. Villella et al., “Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test,” European Journal of Endocrinology, vol. 147, no. 5, pp. 649–654, 2002.
[33] E. Cosson, F. Paycha, J. Pares et al., “Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintography,” Diabetic Medicine, vol. 21, pp. 342–348, 2004.
[34] P. Valensi and E. Cosson, “It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia,” Diabetes and Metabolism, vol. 36, no. 2, pp. 91–96, 2010.
[35] G. W. Lyerly, X. Sui, T. S. Church, C. J. Lavie, G. A. Hand, and S. N. Blair, “Maximal exercise electrocardiography responses and coronary heart disease mortality among men with diabetes mellitus,” Circulation, vol. 117, no. 21, pp. 2734–2742, 2008.
[36] T. H. Marwick, M. D. Hordern, T. Miller et al., “Exercise training for type 2 diabetes mellitus: Impact on cardiovascular risk: a scientific statement from the american heart association,” Circulation, vol. 119, no. 25, pp. 3244–3262, 2009.
[37] F. J. Wackers, D. A. Chyun, L. H. Young et al., “Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the detection of ischemia in asymptomatic diabetics (DIAD) study,” Diabetes Care, vol. 30, no. 11, pp. 2892–2898, 2007.
[38] L. H. Young, F. J. Wackers, D. A. Chyun et al., “Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial,” Journal of the American Medical Association, vol. 301, no. 15, pp. 1547–1555, 2009.
[39] C. R. L. Cardoso, G. F. Salles, and W. Deccache, “Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study,” Journal of Diabetes and Its Complications, vol. 17, no. 4, pp. 169–178, 2003.
[40] P. T. Sawicki, S. Kiwitt, R. Bender, and M. Berger, “The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus,” Journal of Internal Medicine, vol. 243, no. 1, pp. 49–56, 1998.